Ed Timm Email & Phone Number

Mobius Therapeutics™ is a commercial stage venture creating a new category of products in ophthalmic surgery: Perioperative Pharmaceuticals. Its first product, Mitosol®, is the only FDA approved formulation of mitomycin-c bearing an ophthalmic indication. Mobius maintains an active sterile injectable pipeline, optimizing molecules for intraoperative delivery, on a sterile surgical field. Please see full prescribing information at www.Mitosol.com and www.EyeAmphadase.com. Defined the opportunity, invented the product solutions, founded the entity, raised investment capital, guided regulatory efforts, received FDA approval, then launched the product. Twelve issued US patents, four issued Japanese patents, two issued Canadian patents, other patents around the world issued, allowed and/or pending.

Pre-clinical medical device venture, focused upon the diagnosis of recurrent acute otitis media. A telemedicine venture, captures highly sensitive diagnostic data distal to the tympanic membrane, with HIPAA compliant transmission of data to a medical professional.

A clinical based materials science venture, focused upon the applications of pyrolytic carbon in implantable medical devices and long term drug delivery.

Pre-clinical drug/device combination product venture. Focused upon solutions for recurrent acute otitis media, by pioneering a new technique and technology: Selective Photodynamic Tympanostomy.

Israeli innovator of capsule endoscopy (the "PillCam") and systems for image acquisition and interpretation. Focused on GI imaging and diagnostics. Responsible for global marketing, marketing communications, professional education, sales education, web based promotion, IR/PR, corporate events, and exhibitions. Responsibility to US, EU, Japan, Australia, and ROW subsidiaries. Acquired by Medtronic, 2015.

St. Louis, Missouri, Us

Vertically integrated microsurgical device manufacturer, targeting sub-specialty markets in ophthalmology and neurosurgery. Created then managed sales, marketing, business development, and R&D for ophthalmic and neurosurgical disciplines. Recruited and managed direct and independent sales forces, established international distribution, positioned, priced, promoted all offerings, prioritized and scheduled R&D, and all business development functions. Five issued US patents. At varying times, managed all strategic and/or tactical functions of the company. From start up to public company with M$200 market capitalization. Exit at IPO and liquidity. Acquired by Bausch + Lomb, 2015.

Increased US market share from 32% to 56%.

Increased Base of Business from M$.4 to M$3.2 during tenure. “Circle of Stars”, 1986, 1987, 1990.